Background. In spite of more than 20 yr of research, the mechanism whereby local anaesthetics act on the brain to mediate anaesthesia still remains unclear. Furthermore, the effect of local anaesthetics on neuronal excitability and synaptic transmission in the hippocampus has not been reported. Thus, the purpose of the present study was to find out the differences between the local anaesthetics, bupivacaine and ropivacaine, in their actions on synaptic transmission of brain in the context of hippocampal field potential.
Anaesthesia is defined as a loss of sensation resulting from pharmacological depression of nerve function or neurological dysfunction. Of the available anaesthetic agents, local anaesthetics have been used to induce regional anaesthesia, alleviate pain, and control seizures.
Bupivacaine and ropivacaine are long-acting local anaesthetics of the amide type, and are highly effective for postoperative pain relief and for intra-labour analgesia. These two agents have structural differences, and bupivacaine is a racemic mixture of its S-and R-enantiomers, whereas ropivacaine consists exclusively of its S-enantiomer. The pharmacodynamic and pharmacokinetic efficacies of bupivacaine and ropivacaine are very similar in animals and humans. 1 2 Bupivacaine and ropivacaine have been used for spinal anaesthesia, and their blocking effects on TTX-resistant Na þ currents in neurones have been reported. 3 4 Moreover, they are also known to have an inhibitory effect on some voltage-gated K þ channels. 5 -7 From the toxicity point of view, bupivacaine is known to have a greater systemic toxicity than ropivacaine and than other local anaesthetics, such as lidocaine and mepivacaine. 8 Some brain areas have been suggested to be heavily involved in general anaesthesia, and it is known that general anaesthetics act on the brain differently during the different stages of anaesthesia. 9 The hippocampus and medial septum of the brain are known to induce behavioural hyperactivity and to mediate the delirium stage of general anaesthesia, and septal and hippocampal inactivation is known to enhance the effects of general anaesthetics. Some studies have reported that complete inactivation of the hippocampus and septum may facilitate the desirable clinical effects of general anaesthetics, including loss of consciousness, pain, voluntary movements, and memory. 10 11 Moreover general anaesthetics are known to have a direct effect on hippocampal interneurones, which regulate the excitability and synchronize neural activities in the hippocampus. 12 13 Field potential is an extracellular potential induced by membrane electromotive force. The field potential at any point in a medium is equal to the sum of potentials resulting from current components, weighed according to their distances and conductivity differences in medium. 14 Field potential measurements have widely been used to study synaptic transmission in the hippocampus, neocortex, and in other brain regions. 15 Field potential in the hippocampal CA1 region represents field excitatory post-synaptic potential (fEPSP). 14 Furthermore, the simultaneous recording of many sites in the brain enables the spatiotemporal patterns of brain networks to be detected. 16 17 Despite more than 20 yr of research, the underlying mechanisms of local anaesthetics on the brain responsible for mediating anaesthesia remain unclear. Moreover, although the effects of local anaesthetics on individual channels in brain neurones have been studied, the differences of the effects on neuronal excitability and synaptic transmission in the hippocampus in the context of systemic toxicity have not been reported upon. In the present study, the effects of bupivacaine and ropivacaine on field potential amplitudes in the CA1 region of rat hippocampal slices were determined using a perfused drug-test method and the MED64 system (Alpha MED Science, Tokyo, Japan).
Methods

Preparation of hippocampal slices
The general procedure used for the preparation of hippocampal slices was as follows. In brief, 3-to 4-week-old Sprague -Dawley rats of both sexes were killed by decapitation after anaesthesia using Zoletil 50 w (50 mg kg 21 ; i.m.). Whole brains were carefully removed, and immediately soaked (within 1 min) in an ice-cold oxygenated incubation solution within. Brains were placed on the ice-cold plate of a vibrating tissue slicer (DTK-1000, DSK, Tokyo, Japan), and transverse slices (300 mm thickness) were prepared. Slices were then incubated in incubation solution, which had been well exposed to a 95% O 2 /5% CO 2 atmosphere for 1 h at room temperature.
Solutions
The ionic composition of incubation solution was (in mM): NaCl 124, KCl 5, KH 2 PO 4 1.2, MgSO 4 1.3, CaCl 2 2.4, glucose 10, and NaHCO 3 24. Its pH was adjusted to 7.4 by continuous bubbling 95% O 2 /5% CO 2 , and its temperature was maintained at 348C in a water bath. The probe coating solution contained 0.1% polyethylenimine in 25 mM borate buffer adjusted to pH 8.4.
Drugs
Zoletil 50 w was obtained from Vibac Laboratories (Carros, France), and bupivacaine and ropivacaine were from Astra Pharmaceuticals (North Ride, Australia). Drugs were added to incubation solution at the final concentrations mentioned later and were applied using a perfusing pump application system, which allowed 2 ml of incubation solution to be supplied to hippocampal slices within 1 min.
Electrophysiological recordings
Electrophysiological recordings were obtained using the 64-channel multielectrode dish of the MED64 system (Panasonic Co., Tokyo, Japan) using a novel twodimensional electroactivity monitoring technique. 18 19 A slice was placed on the centre on the MED probe, which had been treated with a coating solution for 8 h at room temperature, and then positioned to cover the 8Â8 microelectrode array (interpolar distance 300 mm) and photographed. The MED probe was placed on the MED connector and incubation solution oxygenated with 95% O 2 and 5% CO 2 was continuously infused at 2 ml min 21 (at 348C). Evoked field potentials at the 64 sites were simultaneously recorded after selecting one recording site and two stimulation sites. To record evoked field potentials, a pair of single planar microelectrodes delivering bipolar constant current pulses (45 -90 mA, 0.1 ms) was applied. The amplitudes of field potentials recorded in the absence of any drug were used as control values, and field potential amplitudes recorded during drug application were measured. MED64 Performer TM (Panasonic Co.) was used for data analysis.
Statistical analysis
The data were analysed by ANOVA and the Student's t-test using SPSS statistical software (version 10.1). Results are expressed as the mean (SEM), and P-values of ,0.05 were considered statistically significant.
Results
Measurement of field potential on hippocampal CA1 region
The structures of bupivacaine and ropivacaine are presented in Figure 1 . Both are amide type anaesthetics, and possess a lipophilic aromatic ring and a hydrophilic portion linked by amide. Hippocampal slices were positioned for the MED probe array as shown in Figure 2 .
The experiment was carried out by applying a fixed pulse of 45-90 mV. Amplitudes of field potentials in the CA1 region were recorded without drug application for 10 min, and used as control values. The anaesthetics were applied at a rate of 2 ml min 21 until they maximally inhibited field potential. Finally, field potential amplitudes were recorded after washing out with incubation solution for 2 h to investigate recovery rates ( Fig. 3A and B ). Field potential amplitudes were recorded at 1 min intervals ( Fig. 3C and D). Amplitude changes induced by bupivacaine and ropivacaine were expressed as percentages of control values, which were set at 100%.
Effects of bupivacaine and ropivacaine on field potential amplitudes in the CA1 region
Mean field potential amplitudes in CA1 decreased to 102.29 (2.05)%, 50.00 (1.24)%, 7.55 (0.91)%, and 5.12 (0.67)% of control values after treatment with bupivacaine at 0.1, 1, 10, and 100 mg ml 21 , respectively ( Fig. 4, left) . Similarly, field potential amplitudes in CA1 decreased to 103.25 (0.94)%, 64.47 (3.19)%, 18.63 (1.57)%, and 0.30 (0.30)% of control values after treatment with ropivacaine at 0.1, 1, 10, and 100 mg ml 21 , respectively ( Fig. 4, right) .
These reductions in field potential induced by bupivacaine or ropivacaine showed similar tendencies and the applications of bupivacaine or ropivacaine to CA1 significantly decreased field potential amplitudes in a dosedependent manner. Bupivacaine and ropivacaine at 0.1 mg ml 21 had no significant effect on field potential amplitude.
Time to reach maximum field potential amplitude inhibition in CA1
Times to reach maximum field potential inhibition in CA1 by the two anaesthetics were determined by monitoring field potentials for 90 min. Times to reach maximum field potential inhibition in the CA1 region by bupivacaine at 0.1, 1, 10, and 100 mg ml 21 were 90.00 (0.01), 60.59 (1.48), 47.45 (1.05), and 25.32 (1.73) min, respectively ( Fig. 5, left) . Times to reach maximum field potential inhibition in CA1 by ropivacaine at 0.1, 1, 10, and 100 mg ml 21 were 90.00 (0.01), 60.62 (0.60), 39.98 (0.55), and 7.00 (0.34) min value, respectively (Fig. 5, right) .
Times to reach maximum field potential inhibition in CA1 by bupivacaine or ropivacaine showed similar tendencies and the applications of bupivacaine or ropivacaine for 90 min to CA1 inhibited hippocampal field potential amplitudes dose-dependently. Furthermore, the inhibitory effects of bupivacaine at 10 and 100 mg ml 21 on field potential were less than those of ropivacaine.
Recovery of bupivacaine-or ropivacaine-induced field potential amplitude inhibition in CA1 after washout
After maximally blocking field potential amplitudes in hippocampal slices with bupivacaine or ropivacaine, incubation solutions were washed out and field potential amplitude recovery rates were measured over 2 h. Field potential amplitudes after bupivacaine treatment at 0.1, 1, 10, and 100 mg ml 21 were recovered by washout to 101.93 (Fig. 6, left) . Field potential amplitudes in the CA1 region after ropivacaine treatment at 0.1, 1, 10, and 100 mg ml 21 recovered to 113.78 (1.08)%, 101.02 (2.92)%, 104.89 (1.78)%, and 0.29 (0.13)% of the control values, respectively (Fig. 6, right) .
Recoveries of field potential amplitude after washout after bupivacaine or ropivacaine treatments were found to differ. Recovery rate by washout after bupivacaine showed dose-dependency, but recoveries after ropivacaine followed the all-or-none principle, and in particular, washout after treatment with ropivacaine at 100 mg ml 21 did not recover field potential.
Discussion
The purpose of the present study is to determine the action of the local anaesthetics, bupivacaine and ropivacaine, on synaptic transmission in the brain by measuring field potentials in the hippocampus. The release of excitatory neurotransmitters causes local changes in membrane potentials, that is, EPSPs. EPSPs generate potential gradients along membranes that increase field potentials, which reflect the activities of hundreds to thousands of neurones. Furthermore, field potentials in the hippocampal CA1 region are known to represent fEPSP. 14 In the present study, treatments of CA1 with bupivacaine or ropivacaine were found to significantly decrease field potential amplitudes in CA1 in a dose-dependent manner, which demonstrates that local anaesthetics inhibit neuronal excitability and synaptic transmission in the hippocampus. Moreover, field potential amplitude inhibitions by bupivacaine and ropivacaine showed similar tendencies.
Bupivacaine and ropivacaine have similar chemical properties, such as pKa values and plasma protein binding affinities. Comparative clinical studies on these two anaesthetics have demonstrated that they have similar epidural and axillary block potencies with respect to sensory anaesthesia. 18 -21 Moreover, bupivacaine and ropivacaine have similar effects on pain relief and both have low motor block effects. 22 In the present study, times to reach maximum field potential amplitude inhibition by bupivacaine and ropivacaine were also found to be dose-dependent. However, in terms of times required to reach maximum field potential inhibition, bupivacaine took longer than ropivacaine.
The duration of the effect of a local anaesthetic depends on the contact time between it and nerve fibres and on the concentration of local anaesthetic molecules at nerve fibres. An ideal local anaesthetic has a rapid onset, a prolonged analgesic action, and causes no motor block. Ropivacaine largely fulfils these requirements and provides an excellent anaesthetic effect when used as a peripheral nerve block. It has been previously reported in terms of upper and lower extremity blocks that ropivacaine acts faster than bupivacaine. 23 24 In the present study, recovery rates were determined after washing with incubation solution. Recovery rates after bupivacaine treatment occurred dose-dependently, whereas recovery rates after ropivacaine followed the all-or-none principle. Ropivacaine treatments below 100 mg ml 21 showed complete recovery after washout, but field potentials were not recovered by washout after treatment with ropivacaine 100 mg ml 21 . This suggests that ropivacaine and bupivacaine have similar anaesthetic effects, but that ropivacaine is less toxic than bupivacaine.
Numerous studies have shown that the toxicities of local anaesthetics arise from depressive effects on excitatory tissues, which include the central nervous system (CNS) and heart. The greater toxicity of bupivacaine is attributed to its lipophilic properties, which is known to contribute generally to the toxicities of local anaesthetics. Several studies have shown that bupivacaine has cytotoxic effects on the CNS, heart, and kidney, 25 -27 and clinical studies have concluded that ropivacaine is less toxic to the CNS and heart than bupivacaine when administered i.v. to conscious adult human volunteers. 25 26 Bupivacaine and ropivacaine have been applied in equal concentration and volume in most clinical cases. 28 An equal concentration of bupivacaine and ropivacaine has similar potency and toxicity. 29 -32 However, we suggest that systemic toxicity may be greater for bupivacaine.
The present study shows that bupivacaine and ropivacaine inhibit field potential amplitudes in the hippocampal CA1 region, which suggests that local anaesthetics decrease neuronal activity in CA1 and, in particular, that they decrease synaptic transmission. In conclusion, our results suggest that the inhibitory effects of bupivacaine and ropivacaine on hippocampal field potential amplitude and the recovery rate after washout after bupivacaine or ropivacaine treatment represent the underlying mechanism of the systemic toxicity of these local anaesthetics.
